Results 191 to 200 of about 273,377 (304)

Brain tumor patients' rights and the power of patient advocacy: The current international landscape. [PDF]

Neurooncol Pract
Oliver K, Granero A, Berankova A, Miller C, Hindson C, La Haye C, Tse C, Mungoshi C, Leach D, Arons D, Keegan F, Bulbeck H, Adams H, Dirksje Boer J, Wallgren K, Syed K, Hynes L, Gatellier L, Magiera M, Lim M, Campbell M, Willmarth N, Garg N, Riis Olsen P, Rogers S, Gupta T, Mitchell Skinner T, Moue Y.   +27 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Aligning Public Health, Health Care, Law and Policy: Medical-Legal Partnership as a Multilevel Response to the Social Determinants of Health [PDF]

, 2012
Tyler, Elizabeth Tobin
core   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Patient advocacy and support groups in India: focus on lung cancer. [PDF]

Lancet Reg Health Southeast Asia
Noronha V, Mahajan V, Prakash R, Sharma S, Prabhash K.   +4 more
europepmc   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Identifying and addressing the needs of caregivers of patients with cancer: evidence on interventions and the role of patient advocacy groups. [PDF]

Future Oncol
Dave R, Friedman S, Miller-Sonet E, Moore T, Peterson E, Fawzy Doran J, Wolf Gianares B, Schuler KW, Wilson T.   +8 more
europepmc   +1 more source

Medical-Legal Partnerships as a Value-Add to Patient-Centered medical Homes [PDF]

, 2011
Romney, Martha, RN,MS,JD,MPH
core   +1 more source

Clinical Ethics and Patient Advocacy [PDF]

North Carolina Medical Journal, 2009
openaire   +2 more sources

Patients on statins with elevated transaminases: Frequency of follow‐up creatine kinase testing and gastroenterology referral

British Journal of Clinical Pharmacology, EarlyView.
Abstract Purpose To quantify how often creatine kinase (CK) is measured after newly elevated aminotransferases in statin users, and whether absent CK data are associated with gastroenterology (GI) referrals. Methods Retrospective chart review of adult outpatients on statins with a first alanine/aspartate aminotransferase (ALT/AST) elevation during a 5 ...
Faris Shweikeh, Anas Kartoumah, Rajshri Joshi, Anjali Nadihaan, Mohammed Mouchli, Inderprit Singh   +5 more
wiley   +1 more source